17 November 2015



LONDON, UK, Tuesday 17 November, 11:15 GMT Norgine B.V. today announced it has opened its new £4.5 million temperature controlled warehouse on its current site in Hengoed, Wales.

This new investment exemplifies further Norgine’s commitment to remain a competitive and sustainable business in the long term. Through this investment, Norgine will continue to meet the needs of patients worldwide by delivering high quality products, while adhering to stringent compliance requirements that regulate the pharmaceutical sector.

Norgine has been manufacturing products in Hengoed, Wales since 1969. It is its primary production facility for its leading products, MOVICOL® and MOVIPREP®. Norgine employs around 328 full time staff which makes it the largest pharmaceutical employer in Wales.


Meirion Richards, Site Director, Norgine Hengoed said, “Norgine is very proud to have been a key employer in Hengoed since 1969. Through our investments in our Welsh site, Norgine has been able to increase production to supply medicines to patients worldwide at the right time and right price. Today’s warehouse opening is significant for Norgine because it highlights our long term objective to remain a centre of excellence as an EU specialist pharma company.”


Ken Skates, The Deputy Minster for Culture, Sport and Tourism commented, “I am delighted to be opening this new warehouse. This major investment by Norgine is a vote of confidence in the Hengoed site and the Life Sciences sector in Wales. As one of our Anchor Companies Norgine are playing a key role in realising our ambition to create a thriving Life Sciences sector in Wales and deliver economic growth and high-quality jobs.”


View Norgine’s Hengoed warehouse here



Notes to Editors


About Norgine

Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2014, Norgine’s total revenue was €296 million and the company employs over 1,000 people.

Norgine provides expertise and ‘know how’ in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients. Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.

Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France.

For more information, please visit

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit

NORGINE and the sail logo are trademarks of the Norgine group of companies.

Media Contacts:

Isabelle Jouin, T: +44 (0)1895 453643

Charlotte Andrews, T: +44 (0)1895 453607

Follow us @norgine